Innocan Pharma Corporation announced the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelines. To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness. Innocan is now initiating the following essential development steps that are expected to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases: The definition of the physical and chemical specifications of LPT-CBD as required from a pharmaceutical product.

The expansion of LPT-CBD production from small laboratory quantities to large quantities in pharmaceutical grade.